Industry in brief | IFF, Nature’s Sunshine, PharmaSGP

Industry in brief | IFF, Nature’s Sunshine, PharmaSGP

18 February 2022 - Deborah Wilkes

  • IFF is acquiring Health Wright Products
  • Nature’s Sunshine has created a sustainability role
  • PharmaSGP has released financial results

IFF to acquire Health Wright Products

Ingredients specialist IFF is acquiring Health Wright Products – the US-based contract manufacturer of dietary supplements – for an undisclosed sum.

Founded in 1995, Health Wright Products generated sales of around USD100 million in 2021. The privately-owned company employs more than 225 people.

IFF said Health Wright Products was a “long-time” business partner of its Health & Biosciences probiotics business.

The transaction is expected to close in the first quarter of 2022.

Nature’s Sunshine creates sustainability role

Nature’s Sunshine has given Trent McCausland the newly-created position of vice president of global sustainability and transparency.

The US-based vitamins, minerals and supplements (VMS) specialist said the new position was “part of its commitment to sustainable improvements to its sourcing, manufacturing and other operations processes”.

McCausland will be responsible for “ensuring that Nature's Sunshine's ingredients are provided by suppliers who apply sustainable harvesting and ethical labour practices, and Nature's Sunshine's manufacturing facilities continue reducing their environmental footprint”.

McCausland joined Nature’s Sunshine in 2020, and has had a number of positions in the company’s supply chain team.

PharmaSGP releases financial results

PharmaSGP says it generated sales of around EUR65 million (USD73 million) in 2021, reaching the upper end of its published guidance.

The German consumer healthcare company acquired a portfolio of four OTC brands from GlaxoSmithKline (GSK) on 31 August 2021 (click here to read the News story).

The deal gave PharmaSGP the Baldriparan sleep aids plus the Formigran, Kamol and Spalt pain therapy brands.

Eight countries were covered by the deal, including Austria, the Czech Republic, France, Germany, Hungary, Poland, Slovakia and Switzerland.

PharmaSGP paid around EUR80 million for the portfolio of brands which generated sales of more than EUR15 million in 2020.

The company will publish its full financial results for 2021 on 15 March 2022.

Click tags below for more information on topics:

Nature's Sunshine PharmaSGP

Back to Industry News

Share this page: